Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

49.58USD
10:28pm IST
Change (% chg)

$0.90 (+1.86%)
Prev Close
$48.67
Open
$48.89
Day's High
$50.27
Day's Low
$48.89
Volume
53,052
Avg. Vol
277,354
52-wk High
$64.94
52-wk Low
$30.16

Latest Key Developments (Source: Significant Developments)

Global Blood Therapeutics Q2 Loss Per Share $1.01
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.01.Q2 EARNINGS PER SHARE ESTIMATE $-0.96 -- REFINITIV IBES DATA.  Full Article

Global Blood Therapeutics Announces Proposed Public Offering Of Common Stock
Wednesday, 26 Jun 2019 

June 25 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - AGREEMENT TO SELL APPROXIMATELY $200.0 MILLION IN SHARES OF ITS COMMON STOCK IN A REGISTERED UNDERWRITTEN PUBLIC OFFERING.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING, EXISTING CAPITAL RESOURCES TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR.  Full Article

Gbt Reports Recent Business Progress And Fourth Quarter And Year-End 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 27 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.93.Q4 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $591.8 MILLION AT DECEMBER 31, 2018.  Full Article

Global Blood Therapeutics announces proposed public offering of common stock
Friday, 7 Dec 2018 

Dec 6 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC SAYS ANNOUNCED AGREEMENT TO SELL $150 MILLION IN SHARES OF COMMON STOCK IN REGISTERED UNDERWRITTEN PUBLIC OFFERING.GLOBAL BLOOD THERAPEUTICS -TO USE OFFERING PROCEEDS, EXISTING CAPITAL RESOURCES TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR TO TREAT SICKLE CELL DISEASE.  Full Article

Gbt Announces Positive 24-Week Results From Phase 3 HOPE Study
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES POSITIVE 24-WEEK RESULTS FROM PHASE 3 HOPE STUDY DEMONSTRATING CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN HEMOGLOBIN AND CLINICAL MEASURES OF HEMOLYSIS AND A FAVORABLE SAFETY PROFILE.GLOBAL BLOOD THERAPEUTICS INC - INTERIM ANALYSIS OF DATA FROM 1500 MG COHORT OF HOPE-KIDS 1 STUDY CONSISTENT WITH PHASE 3 HOPE- RESULTS.GLOBAL BLOOD THERAPEUTICS INC - CONTINUING TO GENERATE EFFICACY AND SAFETY DATA ON AN ADDITIONAL 118 PATIENTS IN HOPE STUDY.GLOBAL BLOOD THERAPEUTICS INC - THERE WERE NO DRUG-RELATED DISCONTINUATIONS DUE TO ADVERSE EVENTS.GLOBAL BLOOD THERAPEUTICS INC - THERE WAS NO EVIDENCE OF IMPAIRMENT OF TISSUE OXYGENATION..  Full Article

Global Blood Therapeutics Reports Q2 Loss Per Share Of $0.78
Friday, 3 Aug 2018 

Aug 2 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND PROVIDES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.78.Q2 EARNINGS PER SHARE VIEW $-0.88 -- THOMSON REUTERS I/B/E/S.  Full Article

GBT Announces Positive Top-Line Data From Part A Of The Phase 3 Hope Study Of Voxelotor In Sickle Cell Disease
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES POSITIVE TOP-LINE DATA FROM PART A OF THE PHASE 3 HOPE STUDY OF VOXELOTOR IN SICKLE CELL DISEASE.GLOBAL BLOOD THERAPEUTICS INC - PHASE 3 HOPE STUDY PRIMARY ENDPOINT ACHIEVED.GLOBAL BLOOD THERAPEUTICS - MET FDA ON JUNE 25 AND IS IN DISCUSSIONS ON POTENTIAL ACCELERATED APPROVAL BASED ON HEMOLYTIC ANEMIA EFFICACY ASSESSED BY PRIMARY ENDPOINT.GLOBAL BLOOD THERAPEUTICS INC - VOXELOTOR WAS GENERALLY SAFE AND WELL TOLERATED WITH SIMILAR SAFETY PROFILES BETWEEN TWO DOSES.GLOBAL BLOOD THERAPEUTICS INC - "BASED UPON VOXELOTOR'S ROBUST IMPACT ON HEMOLYTIC ANEMIA, WE BELIEVE IT MEETS STANDARD FOR ACCELERATED APPROVAL".GLOBAL BLOOD THERAPEUTICS INC - APPROVAL BASED ON HEMOLYTIC ANEMIA EFFICACY AS ASSESSED BY PRIMARY ENDPOINT.  Full Article

GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Global Blood Therapeutics Inc ::GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD).  Full Article

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - ANNOUNCED AN AGREEMENT TO SELL $100.0 MILLION IN SHARES OF ITS COMMON STOCK.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE.  Full Article